| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | Protein Having Prolyl Oligopeptidase Activity, Nucleic Acid Encoding Same and Method for Producing and Using Same | US12581304 | 2009-10-19 | US20100086558A1 | 2010-04-08 | Jen-Tao Chen; Mei-Li Chao; Wen-Shen Chu; Chiou-Yen Wen |
| Proteins isolated from Coprinus clastophyllus having prolyl oligopeptidase activity, nucleic acids encoding the protein and methods for producing and using the protein, wherein SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:9 and SEQ ID NO:10 must be contained therein to at least 60% similarity. The proteins and nucleic acids have improved heat stability and perform more favorably in vivo having optimum activity conditions around 40 degrees centigrade and around pH 7, and can therefore be used in medicaments for the treatment of celiac disease caused by proline abundant gluten or other applications. | ||||||
| 62 | Compositions and Methods for Enhanced Gastrointestinal Stability of Oligopeptides and Polypeptides | US12089705 | 2006-10-11 | US20080311161A1 | 2008-12-18 | Jonathan David Gass |
| Methods and compositions are provided for stabilizing polypeptides for oral administration, particularly where enteric delivery is desirable. By administering the polypeptides with a bile sequestering agent, the stability of the polypeptide can be increased. Pharmaceutical formulations for this purpose are provided. | ||||||
| 63 | METHODS FOR DIAGNOSING CELIAC SPRUE AND REAGENTS USEFUL THEREIN | US11927527 | 2007-10-29 | US20080213822A1 | 2008-09-04 | Felix Hausch; Gary Gray; Lu Shan; Chaitan Khosla |
| Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | ||||||
| 64 | ENZYME TREATMENT OF FOODSTUFFS FOR CELIAC SPRUE | US11927533 | 2007-10-29 | US20080213245A1 | 2008-09-04 | Felix Hausch; Gary Gray; Lu Shan; Chaitan Khosla |
| Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | ||||||
| 65 | Ace-Inhibitory Whey Hydrolysates | US11574326 | 2005-08-29 | US20080070828A1 | 2008-03-20 | Jaap de Slegte; Gijsbertus Klarenbeek |
| The invention relates to compounds with an antihypertensive effect. More in particular, the invention relates to releasing ACE (angiotensin I-converting enzyme)-inhibitory peptides from whey proteins. The invention provides a method for enzymatically producing a protein hydrolysate with angiotensin-converting enzyme (ACE)-inhibitory activity, characterized by treatment of a beta-lactoglobulin (BLG)-containing substrate with a broad-spectrum endoprotease in a first reaction step followed by treatment with a proline-specific endoprotease in a second reaction step. The invention also relates to ACE-inhibitory hydrolysates obtainable according to such a method and use of the hydrolysates. | ||||||
| 66 | Enzyme treatment of foodstuffs for Celiac Sprue | US10367405 | 2003-02-14 | US07303871B2 | 2007-12-04 | Felix Hausch; Gary Gray; Lu Shan; Chaitan Khosla |
| Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | ||||||
| 67 | Carboxypeptidases and nucleic acids encoding same | US11073247 | 2005-03-04 | US07091002B2 | 2006-08-15 | Alexander Blinkovsky; Randy Berka; Michael Rey; Elizabeth Golightly; Alan Klotz; Thomas Erik Mathisen; Claus Dambmann |
| The present invention relates to polypeptides having carboxypeptidase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides. The present invention further relates to methods of obtaining protein hydrolysates useful as flavor improving agents. | ||||||
| 68 | Enzyme treatment of foodstuffs for celiac sprue | US10367405 | 2003-02-14 | US20030215438A1 | 2003-11-20 | Felix Hausch; Gary Gray; Lu Shan; Chaitan Khosla |
| Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | ||||||
| 69 | Carboxypeptidases and nucleic acids encoding the same | US08943714 | 1997-10-03 | US06187578B1 | 2001-02-13 | Alexander Blinkovsky; Randy Berka; Michael Rey; Elizabeth Golightly; Alan Klotz; Thomas Erik Mathisen; Claus Dambmann; Kimberly M. Brown |
| The present invention relates to polypeptides having carboxypeptidase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides. The present invention further relates to methods of obtaining protein hydrolysates useful as flavor improving agents. | ||||||
| 70 | Treatment for Gastroesophageal Reflux Disease Caused by a Neurological Disorder | US15897597 | 2018-02-15 | US20180169158A1 | 2018-06-21 | Brian C. Lue |
| An embodiment is a method of mitigating or treating Gastroesophageal Reflux Disease (GERD) caused by a neurological disorder that includes administering an effective amount of a medicament that includes a supernatant resulting from culturing Lactobacillus bulgaricus B-30892 bacteria to a human to mitigate or treat GERD caused by a neurological disorder. | ||||||
| 71 | Use of galerina marginata genes and proteins for peptide production | US15437359 | 2017-02-20 | US09932571B2 | 2018-04-03 | Heather E. Hallen-Adams; John S. Scott-Craig; Jonathan D. Walton; Hong Luo |
| The present invention relates to compositions and methods comprising genes and peptides associated with cyclic peptides and cyclic peptide production in mushrooms. In particular, the present invention relates to using genes and proteins from Galerina species encoding peptides specifically relating to amatoxins in addition to proteins involved with processing cyclic peptide toxins. In a preferred embodiment, the present invention also relates to methods for making small peptides and small cyclic peptides including peptides similar to amanitin. Further, the present inventions relate to providing kits for making small peptides. | ||||||
| 72 | PROLINE-SPECIFIC ENDOPROTEASE AND USE THEREOF | US15314825 | 2015-06-03 | US20170198272A1 | 2017-07-13 | Jan Metske VAN DER LAAN; Peter Jozef Ida VAN DE VONDERVOORT; Chantal CHRISTIS; Martine SPAANS; Angela DE BRUINE-PAULUS |
| The present invention relates to a polypeptide having proline-specific endoprotease activity, wherein the polypeptide has less than 70% residual activity when the polypeptide has been kept at a temperature of 65° C. for 15 min.The invention further relates to a polypeptide having proline-specific endoprotease activity comprising an amino acid sequence according to SEQ ID NO: 1, wherein SEQ ID NO: 1 comprises at least one amino acid substitution selected from the group consisting of P469A, P469C, P469D, P469E, P469F, P469G, P469H, P469I, P469K, P469L, P469M, P469N, P469Q, P469R, P469S, P469T, P469V, P469W, P469Y, a nucleic acid encoding a polypeptide having proline-specific endoprotease activity, a method of making a variant polypeptide having proline-specific endoprotease activity, a recombinant host cell and a method of producing the polypeptide and a process for the preparation of a food or feed product wherein the polypeptide is used. | ||||||
| 73 | ENZYME TREATMENT OF FOODSTUFFS FOR CELIAC SPRUE | US15403886 | 2017-01-11 | US20170119860A1 | 2017-05-04 | Felix Hausch; Gary Gray; Lu Shan; Chaitan Khosla |
| Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | ||||||
| 74 | HYDROGELS OF METHACRYLIC HYALURONIC ACID DERIVATIVES FOR ORAL ENZYME THERAPY IN CELIAC DISEASE | US15307790 | 2015-05-06 | US20170049896A1 | 2017-02-23 | Giovanna Pitarresi; Fabio Salvatore Palumbo; Gaetano Giammona |
| The present invention relates to a composition comprising hydrogels from functionalized hyaluronic acid derivatives, said hydrogels loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP) intended for the oral treatment of celiac disease. Specifically, this invention concerns a one-pot methodology useful to prepare methacrylic derivatives of hyaluronic acid, through the formation of a specific active group on hydroxyl groups of hyaluronic acid, the subsequent substitution of the inserted active group with ethylenediamine and finally, the reaction with methacrylic anhydride. The obtained methacrylic hyaluronic acid derivatives are used to prepare hydrogels through irradiation and loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP). The ability of prepared hydrogels to allow the enzyme release, as active form in simulated gastrointestinal fluids is proved. | ||||||
| 75 | MEDICAMENT AND METHOD FOR TREATING INNATE IMMUNE RESPONSE DISEASES | US15101630 | 2014-12-11 | US20160346364A1 | 2016-12-01 | Maaike Johanna BRUINS; Luppo EDENS; Lenneke NAN |
| This invention relates to a medicament or a dietary supplement comprising the Aspergillus niger aspergilloglutamic peptidase that is capable of hydrolyzing plant food allergens, and more particularly, alpha-amylase/trypsin inhibitors, thereby treating diseases due to an innate immune response in humans, and/or allowing to delay the onset of said diseases. The present invention relates to the discovery that the Aspergillus niger aspergilloglutamic peptidase is capable of hydrolyzing alpha-amylase/trypsin inhibitors that are present in wheat and related cereals said inhibitors being strong inducers of innate immune response. Furthermore, the present invention relates to a method for hydrolyzing alpha-amylase/trypsin inhibitors comprising incubating a composition for food consumption comprising alpha-amylase/trypsin inhibitors with the Aspergillus niger aspergilloglutamic peptidase, wherein the inhibitors are hydrolyzed. It also relates to an enzyme composition comprising the Aspergillus niger aspergilloglutamic peptidase and an additional enzyme, and to foodstuff comprising the Aspergillus niger aspergilloglutamic peptidase. | ||||||
| 76 | USE OF AN ACIDIC SOFT DRINK TO ENHANCE THE EFFICACY OF A GLUTEN-DIGESTING ENZYME | US14915973 | 2014-08-20 | US20160213756A1 | 2016-07-28 | Maaike Johanna BRUINS; Frits KONING; Veronica MONTSERRAT |
| This invention relates to the use of an acidic soft drink for improving the efficiency of gluten digestion and more specifically of a gluten-digesting enzyme supplement. Said use allows maintaining or enhancing gastrointestinal comfort in celiac or non-celiac gluten sensitive individuals, or delaying the onset of gastrointestinal discomfort in non-celiac gluten sensitive healthy individuals using a reduced amount of gluten-digesting enzyme. Furthermore, it relates to an acidic soft drink having a pH in the range of 2 to 3.5 for use to support gluten digestion, and to prevent gastrointestinal discomfort following the ingestion of a gluten-containing meal by a gluten-sensitive consumer. | ||||||
| 77 | EPITOPE VACCINE FOR LOW IMMUNOGENIC PROTEIN AND PREPARING METHOD AND USAGE THEREOF | US14891351 | 2014-05-14 | US20160206732A1 | 2016-07-21 | Rongxiu LI; Li ZHANG; Conghao ZHONG; Chao CHENG; Aizhang XU; Wuguang LU; Zhibing Lin |
| The present invention provides recombinant protein carrying an epitope. The recombinant protein has a skeleton structure from carrier protein, and a low immunogenic protein epitope is imported through splicing, replacement, and/or insertion to at least one molecular surface amino acid residue area of the carrier protein. The carrier protein has at least one T cell epitope, and the recombinant protein can effectively excite immunoreaction of an organism to the low immunogenic protein epitope. | ||||||
| 78 | NOVEL DIAGNOSTIC AND THERAPEUTIC TARGET IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES | US14709305 | 2015-05-11 | US20150329646A1 | 2015-11-19 | Chad Brokopp; Simon Hoerstrup |
| Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for Fibroblast Activation Protein (FAP) expression in a body fluid is provided as well as therapeutic means based thereon. | ||||||
| 79 | PREPARATION OF A STABLE BEVERAGE | US14650449 | 2013-12-10 | US20150307823A1 | 2015-10-29 | Johanna Henrica Gerdina Maria MUTSAERS; Luppo EDENS; Wilbert Herman Marie HEIJNE |
| The present invention relates to a process for the preparation of a beverage comprising adding a proline-specific protease and a polyphenoloxidase to the beverage, and preparing the beverage, and a beverage obtainable by the process of the present invention. | ||||||
| 80 | New Proteases Able to Hydrolyze Gluten Peptides and Proteins at Acidic PH, from the Actinomycete Actinoallomurus | US14356122 | 2012-11-05 | US20140356345A1 | 2014-12-04 | Linda Cavaletti; Lucia Carrano; Monica Abbondi; Mara Brunati; Anna Taravella |
| The invention relates to a new family of proteolytic enzymes having the ability to hydrolize at a p H between 3 and 8 gluten olygopeptides which are resistant to cleavage by gastric and pancreatic enzymes and whose presence in the intestinal lumen results in toxic effects. The enzymes have been identified as endopeptidases of the S8/S53 family and are produced by an Actinoallomurus strain. The object of the invention includes also methods for producing enzymes composition comprising the endopeptidases by cultivation of native Actinoallomurus strains, mutants thereof, or recombinant host cells comprising nucleic acids codifying for the endopeptidases. Said nucleic acids constitute a further object of the invention. The enzyme compositions comprising at least one endopeptidase of the invention are useful for the treatment and/or prevention of celiac sprue, dermatitis herpetiformis and any other disorder associated with gluten intolerance as ingredients of pharmaceutical formulations or as additives of foods and drinks. | ||||||
QQ群二维码
意见反馈
意见反馈